{"id":27543,"date":"2024-04-09T16:17:02","date_gmt":"2024-04-09T10:47:02","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=27543"},"modified":"2025-09-10T10:43:10","modified_gmt":"2025-09-10T05:13:10","slug":"ctx130-for-advanced-clear-cell-renal-cell-carcinoma","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma","title":{"rendered":"CTX130 – CAR T Cell Therapy Offers New Hope for Advanced Clear Cell Renal Cell Carcinoma: AACR 2024"},"content":{"rendered":"\n

Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases commands the majority of treatment focus due to its predominance.<\/p>\n\n\n\n

Currently, the primary treatment revolves around checkpoint inhibitors (CPIs) and tyrosine kinase inhibitors (TKIs). However, prognosis takes a downturn when patients progress on these drug classes, highlighting the pressing need for innovative solutions.<\/p>\n\n\n\n

At AACR 2024, findings from a Phase 1 (COBALT-RCC) trial investigating allogeneic CAR T cell treatment (CTX130) in patients with advanced clear cell renal cell carcinoma are encouraging.CTX130 uses T cells from healthy donors edited to target CD70 and to disrupt the TRAC and \u03b22M genes, which should reduce graft vs. host disease and donor rejection.<\/p>\n\n\n\n

Long-term follow-up and translational data from the COBALT-RCC study underscore the promising antitumor activity and remarkable safety profile of CTX130 in advanced ccRCC patients. Impressively, 81% of patients experienced clinical benefit CR\/partial response\/SD), with 75% exhibiting stable disease and one individual achieving a durable complete response lasting over three years\u2014a landmark achievement in allogeneic, off-the-shelf CAR T cell therapy for refractory solid tumors.<\/p>\n\n\n\n

Building upon these findings, CRISPR Therapeutics has developed CTX131, an improved version of CTX130. Currently, patients are being enrolled in a Phase I\/II clinical trial (NCT05795595) to evaluate the potential of this novel therapy in adult patients with relapsed\/refractory solid tumors.<\/p>\n\n\n\n

For more information, refer DelveInsight\u2019s report:
Advanced Renal Cell Carcinoma (RCC) – Market Insight, Epidemiology And Market Forecast – 2032<\/a><\/p>\n\n\n\n

FAQs<\/h2>\n\n\n\n
How common is RCC compared to other types of kidney cancer?<\/strong><\/strong>

Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases, commands the majority of treatment focus due to its predominance.<\/p> <\/div>

What were the key findings of Phase 1 COBALT-RCC trial presented at AACR 2024?<\/strong><\/strong>

At AACR 2024, findings from a Phase 1 (COBALT-RCC) trial investigating allogeneic CAR T cell treatment (CTX130) in patients with advanced clear cell renal cell carcinoma are encouraging. CTX130 uses T cells from healthy donors edited to target CD70 and to disrupt the TRAC and \u03b22M genes, which should reduce graft vs. host disease and donor rejection.<\/p> <\/div> <\/div>\n","protected":false},"excerpt":{"rendered":"

Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases commands the majority of treatment focus due to its predominance. Currently, the primary treatment revolves around checkpoint inhibitors (CPIs) and tyrosine […]<\/p>\n","protected":false},"author":14,"featured_media":27544,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17126],"tags":[3057,22035,20587],"industry":[17225],"therapeutic_areas":[17228],"class_list":["post-27543","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-others","tag-aacr","tag-aacr-2024","tag-aacr-conference","industry-pharmaceutical","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nCTX130 Phase I COBALT-RCC Trial Result | AACR 2024<\/title>\n<meta name=\"description\" content=\"At AACR 2024, findings from Phase 1 (COBALT-RCC) trial investigating CTX130 in patients with advanced clear cell RCC are encouraging.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CTX130 Phase I COBALT-RCC Trial Result | AACR 2024\" \/>\n<meta property=\"og:description\" content=\"At AACR 2024, findings from Phase 1 (COBALT-RCC) trial investigating CTX130 in patients with advanced clear cell RCC are encouraging.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-09T10:47:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T05:13:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09161650\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CTX130 Phase I COBALT-RCC Trial Result | AACR 2024","description":"At AACR 2024, findings from Phase 1 (COBALT-RCC) trial investigating CTX130 in patients with advanced clear cell RCC are encouraging.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma","og_locale":"en_US","og_type":"article","og_title":"CTX130 Phase I COBALT-RCC Trial Result | AACR 2024","og_description":"At AACR 2024, findings from Phase 1 (COBALT-RCC) trial investigating CTX130 in patients with advanced clear cell RCC are encouraging.","og_url":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-04-09T10:47:02+00:00","article_modified_time":"2025-09-10T05:13:10+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09161650\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","FAQPage"],"@id":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma","url":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma","name":"CTX130 Phase I COBALT-RCC Trial Result | AACR 2024","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09161650\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma.png","datePublished":"2024-04-09T10:47:02+00:00","dateModified":"2025-09-10T05:13:10+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"At AACR 2024, findings from Phase 1 (COBALT-RCC) trial investigating CTX130 in patients with advanced clear cell RCC are encouraging.","mainEntity":[{"@id":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#faq-question-1757481165201"},{"@id":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#faq-question-1757481174353"}],"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09161650\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09161650\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma.png","width":466,"height":284,"caption":"ctx130-for-advanced-clear-cell-renal-cell-carcinoma"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#faq-question-1757481165201","position":1,"url":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#faq-question-1757481165201","name":"How common is RCC compared to other types of kidney cancer?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"Renal cell carcinoma (RCC) is the most common type of kidney cancer, characterized by various subtypes like clear cell, papillary, chromophore, and collecting duct carcinomas. Clear cell carcinoma, constituting 80% of all RCC cases, commands the majority of treatment focus due to its predominance.","inLanguage":"en-US"},"inLanguage":"en-US"},{"@type":"Question","@id":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#faq-question-1757481174353","position":2,"url":"https:\/\/www.delveinsight.com\/blog\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma#faq-question-1757481174353","name":"What were the key findings of Phase 1 COBALT-RCC trial presented at AACR 2024?","answerCount":1,"acceptedAnswer":{"@type":"Answer","text":"At AACR 2024, findings from a Phase 1 (COBALT-RCC) trial investigating allogeneic CAR T cell treatment (CTX130) in patients with advanced clear cell renal cell carcinoma are encouraging. CTX130 uses T cells from healthy donors edited to target CD70 and to disrupt the TRAC and \u03b22M genes, which should reduce graft vs. host disease and donor rejection.","inLanguage":"en-US"},"inLanguage":"en-US"}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/04\/09161650\/ctx130-for-advanced-clear-cell-renal-cell-carcinoma-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">Others<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Others<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR 2024<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/others\/\" class=\"advgb-post-tax-term\">AACR Conference<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AACR<\/span>","<span class=\"advgb-post-tax-term\">AACR 2024<\/span>","<span class=\"advgb-post-tax-term\">AACR Conference<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 8 months ago"},"absolute_dates":{"created":"Posted on Apr 9, 2024","modified":"Updated on Sep 10, 2025"},"absolute_dates_time":{"created":"Posted on Apr 9, 2024 4:17 pm","modified":"Updated on Sep 10, 2025 10:43 am"},"featured_img_caption":"ctx130-for-advanced-clear-cell-renal-cell-carcinoma","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27543","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=27543"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27543\/revisions"}],"predecessor-version":[{"id":33319,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/27543\/revisions\/33319"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/27544"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=27543"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=27543"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=27543"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=27543"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=27543"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}